Venus Concept Secures FDA Clearance for Venus NOVA Platform Amid Financial Challenges.

Tuesday, Nov 11, 2025 3:09 am ET1min read

Venus Concept (VERO) has received FDA clearance for its Venus NOVA platform, a non-invasive treatment device for body, face, and skin. Despite innovative product developments, the company faces financial challenges, including negative profitability and high debt levels. Revenue growth has declined 32.5% over the past three years, and the company has a negative EPS of -50.78 and a net margin of -68.77%. The Altman Z-Score of -8.22 indicates a high risk of bankruptcy.

Venus Concept Secures FDA Clearance for Venus NOVA Platform Amid Financial Challenges.

Comments



Add a public comment...
No comments

No comments yet